Pierre F Desreumaux

List of Publications by Year
in descending order

254 papers	24,255 citations	10956 71 h-index	7496 151 g-index
274 all docs	274 docs citations	274 times ranked	20414 citing authors

#	Article	IF	Citations
1	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2013, 369, 699-710.	13.9	2,114
2	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2013, 369, 711-721.	13.9	2,001
3	Ustekinumab as Induction and Maintenance Therapy for Crohnâ€™s Disease. New England Journal of Medicine, 2016, 375, 1946-1960.	13.9	1,316
4	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	6.3	996
5	Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 1998, 115, 1405-1413.	0.6	767
6	Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine, 2007, 13, 35-37.	15.2	734
7	Dysbiosis in inflammatory bowel disease. Gut, 2004, 53, 1-4.	6.1	693
8	Activation of the peroxisome proliferator-activated receptor Î³ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Medicine, 1998, 4, 1053-1057.	15.2	568
9	CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. Journal of Clinical Investigation, 2007, 117, 1566-1574.	3.9	490
10	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 1621-1628.e5.	0.6	431
11	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferatorâ€“activated receptor-Î³. Journal of Experimental Medicine, 2005, 201, 1205-1215.	4.2	428
12	Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferatorâ€“Activated Receptor Î³ (PparÎ³) Heterodimer. Journal of Experimental Medicine, 2001, 193, 827-838.	4.2	416
13	Impaired expression of peroxisome proliferator-activated receptor Î³ in ulcerative colitis. Gastroenterology, 2003, 124, 1265-1276.	0.6	370
14	PPARÂ as a new therapeutic target in inflammatory bowel diseases. Gut, 2006, 55, 1341-1349.	6.1	363
15	Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease. Gastroenterology, 2012, 143, 1207-1217.e2.	0.6	323
16	Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology, 1999, 117, 73-81.	0.6	305
17	A Unique PPARÎ³ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity. Molecular Cell, 2001, 8, 737-747.	4.5	279
18	Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion.. Journal of Experimental Medicine, 1994, 179, 703-708.	4.2	274

#	Article	IF	Citations
19	Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease?. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13306-13311.	3.3	273
20	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohnâ€™s Disease After Ileocolonic Resection. Gastroenterology, 2016, 150, 1568-1578.	0.6	251
21	Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease.. Journal of Experimental Medicine, 1992, 175, 293-296.	4.2	242
22	Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. American Journal of Gastroenterology, 2002, 97, 939-946.	0.2	240
23	Review article: mode of action and delivery of 5-aminosalicylic acid â€“ new evidence. Alimentary Pharmacology and Therapeutics, 2006, 24, 2-9.	1.9	233
24	Selective expansion of intraepithelial lymphocytes expressing the HLA-Eâ€“specific natural killer receptor CD94 in celiac disease. Gastroenterology, 2000, 118, 867-879.	0.6	227
25	Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2977-2982.	3.3	213
26	Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology, 1997, 113, 118-126.	0.6	212
27	Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut, 2001, 49, 42-46.	6.1	212
28	Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut, 2012, 61, 78-85.	6.1	210
29	Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. Gut, 2007, 56, 577-583.	6.1	200
30	Impaired expression of the peroxisome proliferatorâ€“activated receptor alpha during hepatitis C virus infection. Gastroenterology, 2005, 128, 334-342.	0.6	194
31	Expression of peroxisome proliferator-activated receptor Î³ (PPARÎ³) in normal human pancreatic islet cells. Diabetologia, 2000, 43, 1165-1169.	2.9	183
32	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8772-8777.	3.3	183
33	Stress-induced disruption of colonic epithelial barrier: role of interferon-Î³ and myosin light chain kinase in mice. Gastroenterology, 2003, 125, 795-804.	0.6	182
34	Role of peroxisome proliferator-activated receptor Î³ and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet, The, 2002, 360, 1410-1418.	6.3	181
35	Natural History of Eosinophilic Gastroenteritis. Clinical Gastroenterology and Hepatology, 2011, 9, 950-956.e1.	2.4	171
36	Effectiveness and Safety of Vedolizumab Induction Therapy forÂPatients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	2.4	168

#	Article	IF	Citations
37	Colonization of Mice byCandida albicansIs Promoted by Chemically Induced Colitis and Augments Inflammatory Responses through Galectinâ€3. Journal of Infectious Diseases, 2008, 197, 972-980.	1.9	161
38	Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators. Journal of Medicinal Chemistry, 2012, 55, 4027-4061.	2.9	160
39	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology, 1996, 110, 768-774.	0.6	158
40	Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Antiâ€“Tumor Necrosis Factor Therapy. Clinical Gastroenterology and Hepatology, 2010, 8, 1048-1055.	2.4	158
41	Anti-inflammatory properties of the Î¼ opioid receptor support its use in the treatment of colon inflammation. Journal of Clinical Investigation, 2003, 111, 1329-1338.	3.9	144
42	Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut, 2001, 49, 544-551.	6.1	139
43	Postoperative Complications after Ileocecal Resection in Crohnâ€™s Disease: A Prospective Study From the REMIND Group. American Journal of Gastroenterology, 2017, 112, 337-345.	0.2	138
44	LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13098-13103.	3.3	136
45	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohnâ€™s disease (ANDANTE I and II). Gut, 2019, 68, 40-48.	6.1	132
46	Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut, 2003, 52, 840-846.	6.1	130
47	Oneâ€year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2017, 46, 310-321.	1.9	128
48	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut, 2014, 63, 1416-1423.	6.1	122
49	Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions. Gastroenterology, 2006, 130, 1962-1974.	0.6	117
50	Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cellular Microbiology, 2007, 9, 1252-1261.	1.1	115
51	Use of Mouse Models To Evaluate the Persistence, Safety, and Immune Modulation Capacities of Lactic Acid Bacteria. Vaccine Journal, 2003, 10, 696-701.	3.2	113
52	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 252-261.	1.9	111
53	Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterologie Clinique Et Biologique, 2003, 27, 987-91.	0.9	107
54	Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2012, 18, 1199-1206.	0.9	105

#	Article	IF	Citations
55	A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease, 2015, 47, 119-124.	0.4	103
56	Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn's disease. Journal of Crohn's and Colitis, 2017, 11, jjw224.	0.6	102
57	Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease.. Gut, 1995, 37, 242-246.	6.1	100
58	Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet, The, 2008, 372, 67-81.	6.3	100
59	Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma.. Journal of Experimental Medicine, 1995, 182, 1897-1904.	4.2	99
60	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2063-2071.	0.9	96
61	CD8+ Cytotoxic T Cells Induce Relapsing Colitis in Normal Mice. Gastroenterology, 2006, 131, 485-496.	0.6	93
62	Impact of vedolizumab therapy on extraâ€intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <scp>OBSERV</scp>â€<scp>IBD</scp> cohort. Alimentary Pharmacology and Therapeutics, 2018, 47, 485-493.	1.9	91
63	Genetically related Escherichia coli strains associated with Crohn's disease. Gut, 2001, 48, 320-325.	6.1	87
64	IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. Journal of Clinical Investigation, 2019, 129, 1910-1925.	3.9	85
65	Anti-inflammatory properties of the Î¼ opioid receptor support its use in the treatment of colon inflammation. Journal of Clinical Investigation, 2003, 111, 1329-1338.	3.9	84
66	Resistin-like molecule Î² regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflammatory Bowel Diseases, 2008, 14, 931-941.	0.9	82
67	Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 533-543.	1.9	81
68	Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut, 2006, 55, 815-823.	6.1	80
69	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	2.4	80
70	Abnormalities in Mucin Gene Expression in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 1999, 5, 24-32.	0.9	79
71	The role of <scp>PPAR</scp>Î³â€mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology. Experimental Dermatology, 2015, 24, 245-251.	1.4	79
72	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunology, 2014, 7, 589-601.	2.7	78

#	Article	IF	Citations
73	Obesity, visceral fat and CrohnÊ¼s disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 574-580.	1.3	77
74	Male gender, active smoking and previous intestinal resection are risk factors for postâ€operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 924-932.	1.9	71
75	Novel PPARÎ³ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis. Inflammatory Bowel Diseases, 2016, 22, 279-292.	0.9	68
76	Eosinophils in allergic reactions. Current Opinion in Immunology, 1996, 8, 790-795.	2.4	67
77	Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor Î± and carnitine palmitoyl acyl-CoA transferase 1A. World Journal of Gastroenterology, 2005, 11, 7591.	1.4	66
78	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. Transplantation, 2004, 78, 1697-1701.	0.5	64
79	GW501516-activated PPARÎ²/Î´ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell and Bioscience, 2012, 2, 34.	2.1	63
80	Visceral fat and gut inflammation. Nutrition, 2012, 28, 113-117.	1.1	62
81	Switching Invariant Natural Killer T (iNKT) Cell Response from Anticancerous to Anti-Inflammatory Effect: Molecular Bases. Journal of Medicinal Chemistry, 2014, 57, 5489-5508.	2.9	62
82	Probiotics in inflammatory bowel disease: a critical review. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 805-820.	1.0	60
83	Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. American Journal of Physiology - Renal Physiology, 2014, 307, G274-G285.	1.6	60
84	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1476-1484.	0.9	59
85	Interferon-Î± in combination with corticosteroids improves systemic mast cell disease. British Journal of Dermatology, 1995, 132, 479-482.	1.4	58
86	Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut, 2002, 50, 25-28.	6.1	58
87	Novel polymeric film coatings for colon targeting: Drug release from coated pellets. European Journal of Pharmaceutical Sciences, 2009, 37, 427-433.	1.9	56
88	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2005, 11, 309.	1.4	56
89	PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention. Current Drug Targets, 2013, 14, 1501-1507.	1.0	52
90	Vascular and Cellular Stress in Inflammatory Bowel Disease: Revisiting the Role of Homocysteine. American Journal of Gastroenterology, 2007, 102, 1108-1115.	0.2	49

#	Article	IF	Citations
91	Effects of urban coarse particles inhalation on oxidative and inflammatory parameters in the mouse lung and colon. Particle and Fibre Toxicology, 2017, 14, 46.	2.8	49
92	Decreased Lymphatic Vessel Density Is Associated With Postoperative Endoscopic Recurrence in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2013, 19, 2084-2090.	0.9	48
93	Intestinal steroidogenesis controls PPARÎ³ expression in the colon and is impaired during ulcerative colitis. Gut, 2015, 64, 901-910.	6.1	47
94	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia, 2002, 16, 1637-1644.	3.3	45
95	Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. Scientific Reports, 2015, 5, 9577.	1.6	45
96	NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. Trends in Microbiology, 2006, 14, 432-438.	3.5	44
97	Preclinical Studies of a Specific PPARÎ³ Modulator in the Control of Skin Inflammation. Journal of Investigative Dermatology, 2014, 134, 1001-1011.	0.3	44
98	The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils. Mucosal Immunology, 2016, 9, 322-335.	2.7	43
99	Saccharomyces cerevisiaeCNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World Journal of Gastroenterology, 2017, 23, 336.	1.4	43
100	Pouchitis Is Associated with Mucosal Imbalance Between Interleukin-8 and Interleukin-10. Inflammatory Bowel Diseases, 2000, 6, 157-164.	0.9	42
101	O-001â€ƒA Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service CrohnÊ¼s Disease Refractory to Anti-TFNÎ±. Inflammatory Bowel Diseases, 2016, 22, S1.	0.9	42
102	NOD2: a potential target for regulating liver injury. Laboratory Investigation, 2008, 88, 318-327.	1.7	41
103	Preliminary study of urinary schistosomiasis in a village in the delta of the Senegal river basin, Senegal. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 401-405.	0.7	38
104	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. Bioorganic and Medicinal Chemistry, 2011, 19, 3777-3786.	1.4	38
105	Functional Polymorphisms in the Regulatory Regions of the VNN1 Gene Are Associated with Susceptibility to Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2013, 19, 2315-2325.	0.9	38
106	Epithelial inflammation response induced by Shigella flexneri depends on mucin gene expression. Microbes and Infection, 2002, 4, 1121-1124.	1.0	36
107	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. Bioorganic and Medicinal Chemistry, 2013, 21, 5383-5394.	1.4	36
108	Similar IL-5, IL-3, and GM-CSF Syntheses by Eosinophils in the Jejunal Mucosa of Patients with Celiac Disease and Dermatitis Herpetiformis. Clinical Immunology and Immunopathology, 1998, 88, 14-21.	2.1	35

#	Article	IF	Citations
109	AIEC colonization and pathogenicity: Influence of previous antibiotic treatment and preexisting inflammation. Inflammatory Bowel Diseases, 2012, 18, 1923-1931.	0.9	35
110	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 533-541.	1.9	35
111	Role of glycogen synthase kinase-3Î² and PPAR-Î³ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. PLoS ONE, 2017, 12, e0171093.	1.1	35
112	Evidence for Eosinophil Activation in Eosinophilie Cystitis. European Urology, 1994, 25, 254-258.	0.9	34
113	How NOD2 mutations predispose to Crohn's disease?. Microbes and Infection, 2007, 9, 658-663.	1.0	34
114	In vivo efficacy of microbiota-sensitive coatings for colon targeting: A promising tool for IBD therapy. Journal of Controlled Release, 2015, 197, 121-130.	4.8	34
115	Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohnâ€™s Disease Patients Classified i2 on the Rutgeerts Score. Digestive Diseases and Sciences, 2016, 61, 2986-2992.	1.1	34
116	Role of the High Affinity Immunoglobulin E Receptor in Bacterial Translocation and Intestinal Inflammation. Journal of Experimental Medicine, 2001, 193, 25-34.	4.2	33
117	Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents. Current Medicinal Chemistry, 2012, 19, 3457-3474.	1.2	33
118	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Alimentary Pharmacology and Therapeutics, 2006, 24, 851-858.	1.9	32
119	Neutrophil Migration During Liver Injury Is Under Nucleotide-Binding Oligomerization Domain 1 Control. Gastroenterology, 2010, 138, 1546-1556.e5.	0.6	32
120	Intestinal steroidogenesis. Steroids, 2015, 103, 64-71.	0.8	32
121	Gut: An underestimated target organ for Aluminum. Morphologie, 2016, 100, 75-84.	0.5	32
122	Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). Clinical and Experimental Immunology, 2000, 122, 180-185.	1.1	31
123	Colon targeting with bacteria-sensitive films adapted to the disease state. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 74-81.	2.0	31
124	4-Oxo-1,4-dihydropyridines as Selective CB₂ Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series. Journal of Medicinal Chemistry, 2010, 53, 7918-7931.	2.9	30
125	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARÎ³. Carcinogenesis, 2013, 34, 2580-2586.	1.3	30
126	Toxicological consequences of experimental exposure to aluminum in human intestinal epithelial cells. Food and Chemical Toxicology, 2016, 91, 108-116.	1.8	30

#	Article	IF	Citations
127	Colonic Inflammation in Mice Is Improved by Cigarette Smoke through iNKT Cells Recruitment. PLoS ONE, 2013, 8, e62208.	1.1	30
128	Advances and Perspectives in the Genetics of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2006, 4, 143-151.	2.4	29
129	No Evidence for an Involvement of the P38 and JNK Mitogen-Activated Protein in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2006, 51, 1443-1453.	1.1	28
130	Cerebro-Spinal Fluid Eosinophilia in Shunt Infections. Neuropediatrics, 1992, 23, 235-240.	0.3	27
131	Pyrogenicity and Cytokine-Inducing Properties ofStreptococcus pyogenes Superantigens: Comparative Study of Streptococcal Mitogenic Exotoxin Z and Pyrogenic Exotoxin A. Infection and Immunity, 2001, 69, 4141-4145.	1.0	27
132	Â-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut, 2007, 56, 974-981.	6.1	27
133	Infliximab failure in cap polyposis. Gut, 2005, 54, 313-314.	6.1	26
134	Novel polymeric film coatings for colon targeting: How to adjust desired membrane properties. International Journal of Pharmaceutics, 2009, 371, 64-70.	2.6	25
135	Systemic Administration of Agonist Peptide Blocks the Progression of Spontaneous CD8-Mediated Autoimmune Diabetes in Transgenic Mice Without Bystander Damage. Journal of Immunology, 2000, 165, 202-210.	0.4	24
136	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut, 2017, 66, 1912-1917.	6.1	24
137	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating Î²7+ T Cells in Crohnâ€™s Disease: Report of the TOSCA Study. Journal of Crohn's and Colitis, 2018, 12, 188-196.	0.6	24
138	Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis. ACS Medicinal Chemistry Letters, 2015, 6, 198-203.	1.3	23
139	Patients with CrohnÊ¼s Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. Inflammatory Bowel Diseases, 2017, 23, 1853-1859.	0.9	23
140	Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1247-1252.	0.8	23
141	Treatments for Crohnâ€™s Diseaseâ€“Associated Bowel Damage: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 847-856.	2.4	23
142	Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohnâ€™s Disease. Digestive Diseases and Sciences, 2020, 65, 1445-1452.	1.1	23
143	Search for evidence of recurring or persistent viruses in Crohn's disease. Apmis, 2007, 115, 962-968.	0.9	22
144	Eosinophilic Enteritis. Digestive Diseases, 2015, 33, 183-189.	0.8	22

#	Article	IF	Citations
145	4-Oxo-1,4-dihydropyridines as Selective CB₂ Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. Journal of Medicinal Chemistry, 2012, 55, 8948-8952.	2.9	21
146	Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the LÃ©mann Index and Inflammatory Bowel Disease Disability Index. Alimentary Pharmacology and Therapeutics, 2020, 51, 889-898.	1.9	21
147	Transdermal Nicotine Decreases Mucosal IL-8 Expression but Has No Effect on Mucin Gene Expression in Ulcerative Colitis. Inflammatory Bowel Diseases, 1999, 5, 174-181.	0.9	20
148	Variants of NOD1 and NOD2 genes display opposite associations with familial risk of crohnÊ¼s disease and anti-saccharomyces cerevisiae antibody levels. Inflammatory Bowel Diseases, 2012, 18, 430-438.	0.9	20
149	Peroxisome Proliferatorâ€“activated Receptor Gamma in the Colon. Journal of Clinical Gastroenterology, 2014, 48, S23-S27.	1.1	20
150	Virtual Screening of CB₂ Receptor Agonists from Bayesian Network and Highâ€Throughput Docking: Structural Insights into Agonistâ€Modulated GPCR Features. Chemical Biology and Drug Design, 2013, 81, 442-454.	1.5	19
151	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. Journal of Crohn's and Colitis, 2017, 11, 1326-1334.	0.6	19
152	Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. Journal of Pharmacy and Pharmacology, 2010, 62, 1676-1684.	1.2	18
153	Peas starchâ€based film coatings for siteâ€specific drug delivery to the colon. Journal of Applied Polymer Science, 2011, 119, 1176-1184.	1.3	18
154	Streptococcal pyrogenic exotoxin A (SPE A) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells. Microbial Pathogenesis, 1997, 23, 265-272.	1.3	17
155	Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in CrohnÊ¼s disease. European Journal of Gastroenterology and Hepatology, 1999, 11, 1113-1120.	0.8	17
156	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohnâ€™s Disease Recurrence. Journal of Crohn's and Colitis, 2016, 11, jjw151.	0.6	17
157	Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohnâ€²s Disease: A French Population-Based Study. Inflammatory Bowel Diseases, 2019, 25, 394-402.	0.9	17
158	Short-term variability of intertidal microphytobenthic production using an oxygen microprofiling system. Marine and Freshwater Research, 2009, 60, 712.	0.7	16
159	Peroxisome proliferatorâ€activated receptor gamma (PPARÎ³) regulates lactase expression and activity in the gut. EMBO Molecular Medicine, 2017, 9, 1471-1481.	3.3	16
160	Characterization of ethylcellulose: starch-based film coatings for colon targeting. Drug Development and Industrial Pharmacy, 2009, 35, 1190-1200.	0.9	15
161	Adalimumab dose escalation is effective and well tolerated in Crohnâ€™s disease patients with secondary loss of response to adalimumab. Digestive and Liver Disease, 2017, 49, 163-169.	0.4	15
162	Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses. PLoS ONE, 2018, 13, e0209681.	1.1	15

#	Article	IF	Citations
163	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2022, 16, 1269-1280.	0.6	15
164	Specific targeting of IL-6 signalling pathway: a new way to treat IBD?. Gut, 2000, 47, 465-466.	6.1	14
165	High carriage of adherent invasive E. coli in wildlife and healthy individuals. Gut Pathogens, 2018, 10, 23.	1.6	14
166	Superantigenic Yersinia pseudotuberculosis Induces the Expression of Granzymes and Perforin by CD4 + T Cells. Infection and Immunity, 2015, 83, 2053-2064.	1.0	13
167	The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. Frontiers in Immunology, 2017, 8, 1052.	2.2	13
168	Switching cannabinoid response from CB2 agonists to FAAH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1322-1326.	1.0	12
169	Acrylamide induces accelerated endothelial aging in a human cell model. Food and Chemical Toxicology, 2015, 83, 140-145.	1.8	12
170	Postâ€operative complications in elderly onset inflammatory bowel disease: a populationâ€based study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1652-1660.	1.9	12
171	Immunobiology of eosinophils in allergy and inflammation. Research in Immunology, 1997, 148, 29-33.	0.9	11
172	Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2001, 107, 739-741.	1.5	11
173	Yersinia pseudotuberculosis Anti-Inflammatory Components Reduce Trinitrobenzene Sulfonic Acid-Induced Colitis in the Mouse. Infection and Immunity, 2004, 72, 2438-2441.	1.0	11
174	Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 832-840.	1.4	11
175	Enzymatically activated coated multiparticulates containing theophylline for colon targeting. Journal of Drug Delivery Science and Technology, 2010, 20, 193-199.	1.4	10
176	In vivo imaging reveals selective <scp>PPAR</scp> activity in the skin of peroxisome proliferatorâ€activated receptor responsive elementâ€luciferase reporter mice. Experimental Dermatology, 2013, 22, 137-140.	1.4	10
177	Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World Journal of Gastroenterology, 2022, 28, 2509-2522.	1.4	10
178	Infectious agents and Crohn's disease. Clinical Microbiology and Infection, 1999, 5, 601-604.	2.8	9
179	Overexpression of leptin mRNA in the mesenteric adipose tissue of inflammatory bowel disease (IBD). Gastroenterology, 2000, 118, A340-A341.	0.6	9
180	CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease. Human Immunology, 2001, 62, 694-700.	1.2	9

#	Article	IF	Citations
181	Evaluation of therapeutic properties of fermented vegetables extract (OM-XÂ®) in the model of colitis induced by Citrobacter rodentium in mice. Journal of Functional Foods, 2014, 10, 117-127.	1.6	9
182	OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study. Journal of Crohn's and Colitis, 2014, 8, S4-S5.	0.6	9
183	A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of Candida Yeasts and Fluconazole in Crohnâ€™s Disease. Journal of Fungi (Basel, Switzerland), 2021, 7, 324.	1.5	9
184	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis (UC). Gastroenterology, 1998, 114, A1028.	0.6	8
185	Mixed Adenocarcinoid Tumor and Crohn's Disease. Journal of Clinical Gastroenterology, 1998, 26, 353-354.	1.1	8
186	Impaired contractile response of mesenteric arteries in Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2000, 14, 1279-1285.	1.9	7
187	Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis.. Gut, 1995, 37, 132-135.	6.1	6
188	Hepatic deficiency of interleukin 10 in chronic hepatitis C. Gastroenterology, 2000, 119, 1411-1412.	0.6	6
189	PPARÎ³ agonists as a new class of effective treatment for ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 959-960.	0.9	6
190	Using a Sodar to Measure Optical Turbulence and Wind Speed for the Thirty Meter Telescope Site Testing. Part I: Reproducibility. Boundary-Layer Meteorology, 2011, 141, 273-288.	1.2	6
191	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. Gastroenterology, 2016, 150, S155.	0.6	6
192	Adherent invasive Escherichia coli (AIEC) strain LF82, but not Candida albicans, plays a profibrogenic role in the intestine. Gut Pathogens, 2021, 13, 5.	1.6	6
193	Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). Gastroenterology, 1998, 114, A958-A959.	0.6	5
194	Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. European Journal of Anaesthesiology, 2003, 20, 957-962.	0.7	5
195	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. PLoS ONE, 2021, 16, e0257281.	1.1	5
196	Invasive ability of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). Gastroenterology, 2000, 118, A342.	0.6	4
197	Saccharomyces Cerevisiae CNCM I-3856 Reduces Digestive Discomfort and Abdominal Pain in Subjects With Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo-Controlled Clinical Trial. Gastroenterology, 2011, 140, S-50.	0.6	4
198	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. Cellular and Molecular Immunology, 2020, 17, 1272-1274.	4.8	4

#	Article	IF	Citations
199	741 4-Oxo-1,4-Dihydroquinoline-3-Carboxamides Derivatives As New Potent and Selective Cb2 Agonists with Anti-Inflammatory and Analgesic Properties in the Gut. Gastroenterology, 2008, 134, A-107.	0.6	3
200	274 Sacharomyces Cerevisiae Cncm I-3856 Decreases Intestinal Pain Through PPAR Alpha Activation in the Gut. Gastroenterology, 2010, 138, S-51.	0.6	3
201	Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. Clinical and Experimental Immunology, 1996, 104, 293-296.	1.1	2
202	Macrophage collections in gastrointestinal biopsies and metabolic disorders: two unusual case reports. Histopathology, 2003, 42, 196-198.	1.6	2
203	Impact of the Yersinia pseudotuberculosis -Derived Mitogen (YPM) on the Murine Immune System. , 2003, 529, 133-135.		2
204	Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo. Gastroenterology, 2011, 140, S-515.	0.6	2
205	Probiotic Yeast Therapy for Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2016, 22, 542-542.	0.8	2
206	Sa1960 Crohn's Disease Patients With High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. Gastroenterology, 2016, 150, S417.	0.6	2
207	Trough Levels and Antibodies to Ustekinumab are not Correlated to Response to Ustekinumab Treatment in Crohn's Disease Patients. Gastroenterology, 2017, 152, S388.	0.6	2
208	Understanding the Mechanism of 5-ASA in Treating Colonic Inflammation. Gastroenterology and Hepatology, 2008, 4, 319-20.	0.2	2
209	Mesenteric obesity in Crohn's disease (CD). Gastroenterology, 1998, 114, A989.	0.6	1
210	Low ileal IL-10 mRNA levels may predict endoscopic recurrence after surgery in a subgroup of patients with Crohn's disease (CD). Gastroenterology, 1998, 114, A1038.	0.6	1
211	Activation of PPARÎ“ protects against colon inflammation by inhibiting TNFA signaling pathways. Gastroenterology, 2000, 118, A864.	0.6	1
212	ThÃ©rapeutique nutritionnelle des maladies inflammatoires chroniques de lâ€™intestin. Nutrition Clinique Et Metabolisme, 2002, 16, 202-205.	0.2	1
213	740 Development of a New Optimized 5-ASA Molecule Ged-0507-34 with Intestinal Anti-Inflammatory and Analgesic Properties. Gastroenterology, 2008, 134, A-106-A-107.	0.6	1
214	Early Involvement of Liver Natural Killer T Cells in Limiting Colonic Inflammation and Application to Disease Treatment. Gastroenterology, 2011, 140, S-1.	0.6	1
215	Clinical Value of Measuring Trough Levels and Human Anti-Chimeric Antibodies in Patients With Inflammatory Bowel Disease Who Lost Response to Infliximab Therapy. Gastroenterology, 2011, 140, S-277.	0.6	1
216	Mo1899 Evaluation and Long-Term Benefit of Deep Remission in Crohn's Disease Patients Treated With Infliximab. Gastroenterology, 2016, 150, S810-S811.	0.6	1

#	Article	IF	Citations
217	Tu1881 HLA B27 Transgenic Rat: A New Animal Model of Postsurgical Ileitis in Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S967.	0.6	1
218	The Presence of Adherent-Invasive Escherichia Coli (AIEC) on the Surgical Specimen is a Predictor of Severe Endoscopic Postoperative Recurrence in Ileal Crohn's Disease. Gastroenterology, 2017, 152, S9.	0.6	1
219	Neoboutonia melleri var velutina Prain: in vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models. BMC Complementary and Alternative Medicine, 2018, 18, 24.	3.7	1
220	Anti-Inflammatory Effect of Recombinant Human Alpha-fetoprotein (rhAFP) in the Model of TNBS-induced Colitis. American Journal of Gastroenterology, 2017, 112, S375-S376.	0.2	1
221	Serosal vascular lesions in Crohn's disease. Gastroenterology, 1995, 108, A808.	0.6	0
222	PathogÃ©nie: aspects immunologiques, infectieux et gÃ©nÃ©tiques. Archives De Pediatrie, 1998, 5, 97s-100s.	0.4	0
223	No bacteria detected by PCR in mesenteric lymph nodes from patients with Crohn's disease (CD). Gastroenterology, 1998, 114, A944-A945.	0.6	0
224	IL-8 in early and chronic ileal lesions of Crohn's disease (CD). Gastroenterology, 1998, 114, A941.	0.6	0
225	Phenotypic changes of intraeptihelial lymphocytes (IELS) in intestinal lesions of Crohn's disease (CD). Gastroenterology, 1998, 114, A968.	0.6	0
226	High level expression of PPARÎ³ in differentiated colon epithelium. Gastroenterology, 1998, 114, A391.	0.6	0
227	<title>Endoscopic fluorescence imaging for early assessment of anastomotic recurrence of Crohn's disease</title>. , 1999, , .		0
228	Chronic stress stimulates organ specific cytokine expression in mice. Gastroenterology, 2000, 118, A881.	0.6	0
229	Laparoscopic surgery reduces peroperative opiold requirement in Crohn's disease. Gastroenterology, 2000, 118, A581.	0.6	0
230	Mesenteric adipose tissue: A major source of TNFA in experimental ileitis in rats. Gastroenterology, 2000, 118, A341.	0.6	0
231	IL-10 hepatic deficit in hepatitis C virus (HCV) infection. Gastroenterology, 2000, 118, A944.	0.6	0
232	Ige receptor affects fecal flora, bacterial translocation and intestinal inflammation. Gastroenterology, 2000, 118, A694.	0.6	0
233	Low ileal IL-10 mRNA levels predict endoscopic recurrence in patients operated on for Crohn's disease (CD). Gastroenterology, 2000, 118, A108-A109.	0.6	0
234	453 Increased interleukin-10 and interluekin-4 mRNA expression in gut mucosa from patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2000, 105, S149.	1.5	0

#	Article	IF	Citations
235	No evidence for involvement of the mitogen-activated protein kinase (MAPK) P38 and JNK pathways in human inflammatory bowel diseases and experimental colitis. Gastroenterology, 2003, 124, A326-A327.	0.6	0
236	PPARÎ³. Inflammatory Bowel Diseases, 2006, 12, S9-S10.	0.9	0
237	[30] INVOLVEMENT OF NOD SIGNALLING IN HEPATOCYTE AND IMMUNE CELLS DURING HEPATITIS. Journal of Hepatology, 2007, 46, S15.	1.8	0
238	703 BACTERIAL RECEPTOR NOD1 REGULATES THE NEUTROPHIL MIGRATION MACHINERY DURING LIVER INJURY. Journal of Hepatology, 2009, 50, S258.	1.8	0
239	Glucagon Like Peptide 2 (GLP2) Receptor Expression is Not Restricted to the Gastrointestinal Tract and is Modulated by Inflammation. Gastroenterology, 2011, 140, S-477.	0.6	0
240	Aluminum Enhances Inflammation and Decreases Healing in Experimental Models of Colitis. Gastroenterology, 2011, 140, S-493.	0.6	0
241	Antibiotics Induced Commensal Flora Disruption Favours Escherichia coli AIEC (LF82) Colonization in Wild Type and NOD2 Knock-out Mice. Gastroenterology, 2011, 140, S-324.	0.6	0
242	Mo2020 Mucin Cys Domain Strengthens the Mucus Barrier During Experimental Intestinal Inflammation. Gastroenterology, 2012, 142, S-721-S-722.	0.6	0
243	One year multiple injections of antigen specific T regulatory lymphocytes in refractory crohnâ€™s disease patients, extension of CATS1 study. Cytotherapy, 2013, 15, S42.	0.3	0
244	Mo1696 Treatment With P28GST, a Recombinant Enzyme From Schistosome Helminth Parasite Prevents Hapten-Induced Colitis by Inducing a Regulatory Th2 Response. Gastroenterology, 2014, 146, S-638.	0.6	0
245	P084 Dissecting the role of PPARgamma in intestinal fibrosis: EMT-activator ZEB1 as new molecular target. Journal of Crohn's and Colitis, 2014, 8, S97.	0.6	0
246	Author's reply to Comment on â€œA randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndromeâ€•by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119â€“24]. Digestive and Liver Disease, 2015, 47, 437-438.	0.4	0
247	OC-005â€…A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohnâ€™s Disease (CD) Refractory to anti-TNFÎ±: UNITI-1. Gut, 2016, 65, A3.2-A4.	6.1	0
248	Mo1909 Adalimumab Dose Escalation Is Effective and Well Tolerated in Crohn's Disease Patients With Secondary Loss of Response to Adalimumab. Gastroenterology, 2016, 150, S813-S814.	0.6	0
249	979 Modulating Peroxisome Proliferator-Activated Receptor Gamma (PPARÎ³): A Potential New Therapeutic Strategy for Lactose Intolerance. Gastroenterology, 2016, 150, S199.	0.6	0
250	Mo1900 Combination Therapy With Infliximab and Methotrexate Does Not Improve Crohn's Disease Outcome and Infliximab Tolerance Compared to Infliximab Therapy Alone. Gastroenterology, 2016, 150, S811.	0.6	0
251	Mo1823 Highlighting of Epidemic Areas of Crohn's Disease in a Population-Based Registry Over 22 Years: Genetic or Environmental Cause?. Gastroenterology, 2016, 150, S785-S786.	0.6	0
252	Mo1898 Continuation or Switch to Another Anti-TNFÎ± After Intestinal Resection in Crohn's Disease Patients Previously Exposed to Anti-TNFÎ±?. Gastroenterology, 2016, 150, S810.	0.6	0

#	Article	IF	Citations
253	Sa1846 The Expression of the Short Isoform of TSLP in the Colon Is Regulated by the Nuclear Receptor PPARÎ³ and Is Impaired During Ulcerative Colitis. Gastroenterology, 2016, 150, S379.	0.6	0
254	Su1868 Dissecting the Role of RAGE in Intestinal Fibrosis. Gastroenterology, 2016, 150, S575.	0.6	0